Shares of Healthcare sector company Grifols moved 0.7% today, and are now trading at a price of $8.23. The mid-cap stock's daily volume was 158,306 compared to its average volume of 1,389,717. The S&P 500 index returned a -0.4% performance.
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company is based in Barcelona and has 27,584 full time employees. Its market capitalization is $6,439,218,176.
2 analysts are following Grifols and have set target prices ranging from $10.76 to $13.47 per share. On average, they have given the company a rating of hold. At today's prices, GRFS is trading -32.0% away from its average analyst target price of $12.11 per share.
Over the last year, GRFS shares have gone down by -30.9%, which represents a difference of -16.1% when compared to the S&P 500. The stock's 52 week high is $13.34 per share and its 52 week low is $5.71. With average free cash flows of $485,944,750.0 that have been growing at an average rate of 38.1% over the last four years, Grifols declining stock performance may not be reflective of the quality of its underlying business.
For a deeper fundamental analysis into Grifols and other market moving stocks, subscribe to our free newsletter today!
